In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...
Comprehensive reviews of the literature related to management and diagnosis of pheochromocytoma are available elsewhere.
Diagnosis. Pheochromocytoma myocarditis. Management. Intra-aortic balloon pump, levosimendan and dobutamine infusion, α-blockade with phentolamine, surgical removal of the pheochromocytoma ...
Diagnosis: Pheochromocytoma -- a catecholamine secreting tumor. A 52-year-old woman presented to the emergency department with recurrent episodes of chest and abdominal pain, dyspnea, palpitations ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Pheochromocytoma occur in the center of the adrenal gland, whereas paraganglioma occur in nerve tissue in the adrenal glands and near certain blood vessels and nerves. Up to 25% of PPGL cases are ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback